Rossari Biotech Ltd (ROSB)

Currency in INR
414.70
-12.60(-2.95%)
Closed·
ROSSARI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
397.10424.35
52 wk Range
375.00663.00
Key Statistics
Bid/Ask
414.70 / 417.10
Prev. Close
414.7
Open
424.35
Day's Range
397.1-424.35
52 wk Range
375-663
Volume
181.48K
Average Volume (3m)
79.69K
1-Year Change
-36.2392%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ROSSARI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
575.50
Upside
+38.78%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth

Rossari Biotech Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 575.50
(+38.78% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
ICICI Securities
Buy520.00+25.39%605.00MaintainOct 21, 2026
ICICI Securities
Buy605.00+45.89%570.00MaintainJul 21, 2026
ICICI Securities
Buy570.00+37.45%660.00MaintainApr 29, 2026

Rossari Biotech Ltd Earnings Call Summary for Q2/2027

  • Rossari Biotech Q2 revenue rose 21% YoY to INR 619.9 crores but missed estimates by 3.61%; stock fell 4.32% to $435 on margin concerns.
  • Export revenue surged 34% YoY to 31% of sales, driven by HPPC and textile chemicals; core B2B EBITDA margin compressed to 14.1% from 14.8%.
  • Net debt declined to INR 221 crores from INR 281 crores; working capital days improved to 86 from 97, with H1 operating cash flow at INR 131 crores.
  • Management guides FY27 revenue growth at mid-to-high teens with ~12% EBITDA margin; freight costs doubled/tripled YoY, pressuring profitability.
  • CapEx of INR 50-75 crores planned for H2 focused on pharma and biosurfactants; B2C segment reached breakeven versus INR 3.7 crore loss last year.
Last Updated: 2026-10-19, 07:48 a/m
Read Full Transcript

Earnings

Latest Release
Oct 17, 2026
EPS / Forecast
7.00 / --
Revenue / Forecast
6.98B / 6.92B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 27.54
Dividend Yield
0.12%
Industry Median 0.72%
Annualized payout
0.50
Paid annually
5-Years Growth
-
Growth Streak

ROSSARI Income Statement

Compare ROSSARI to Peers and Sector

Metrics to compare
ROSSARI
Peers
Sector
Relationship
P/E Ratio
15.0x29.6x4.0x
PEG Ratio
1.300.860.00
Price/Book
1.6x3.4x1.6x
Price / LTM Sales
0.9x3.3x1.2x
Upside (Analyst Target)
38.8%26.6%53.3%
Fair Value Upside
Unlock18.2%6.4%Unlock

Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers home, personal care, and performance chemicals products, such as soaps and detergents; oil and gas division; inks; paints and coatings; ceramics and tiles; pulp and paper; cement; water treatment; performance additives; cleaning, hygiene, and disinfection; surfactants; and textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printing, and sustainable solutions. The company also provides pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, and creams; and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names. In addition, it offers poultry nutrition products comprising vitamin-mineral formulations, toxin binders, individual and cocktail enzymes, liquid nutraceuticals, and supplements or herbal preparations. The company was formerly known as Rossari Labtech and changed its name to Rossari Biotech Limited in December 2003. Rossari Biotech Limited was founded in 1997 and is based in Mumbai, India.

Industry
Chemicals
Employees
585
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
5.69M10.27%2.36B
Other Institutional Investors
11.95M21.57%4.96B
Public Companies & Retail Investors
37.76M68.16%15.66B
Total
55.39M100.00%22.97B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Chari Family Trust9.22%5,110,0002,119,117
UTI Asset Management Company Limited6.36%3,522,6451,460,841

People Also Watch

76.40
ANDS
-3.28%
265.10
KPGR
-3.65%
202.31
CMSN
-0.83%

FAQ

What Is the Rossari Biotech (ROSSARI) Stock Price Today?

The Rossari Biotech stock price today is 414.70 INR.

What Stock Exchange Does Rossari Biotech Trade On?

Rossari Biotech is listed and trades on the India National Stock Exchange.

What Is the Stock Symbol for Rossari Biotech?

The stock symbol for Rossari Biotech is "ROSSARI."

Does Rossari Biotech Pay Dividends? What’s The Current Dividend Yield?

The Rossari Biotech dividend yield is 0.1%%.

What Is the Rossari Biotech Market Cap?

As of today, Rossari Biotech market cap is 22.97B INR.

What Is Rossari Biotech's Earnings Per Share (TTM)?

The Rossari Biotech EPS (TTM) is 27.54.

When Is the Next Rossari Biotech Earnings Date?

Rossari Biotech will release its next earnings report on Jan 18, 2027.

From a Technical Analysis Perspective, Is ROSSARI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Rossari Biotech Stock Split?

Rossari Biotech has split 0 times.

How Many Employees Does Rossari Biotech Have?

Rossari Biotech has 585 employees.

What is the current trading status of Rossari Biotech (ROSSARI)?

As of Oct 25, 2026, Rossari Biotech (ROSSARI) is trading at a price of 414.70 INR, with a previous close of 414.70 INR. The stock has fluctuated within a day range of 397.10 INR to 424.35 INR, while its 52-week range spans from 375.00 INR to 663.00 INR.

What Is Rossari Biotech (ROSSARI) Price Target According to Analysts?

The average 12-month price target for Rossari Biotech is 575.50 INR, with a high estimate of 637 INR and a low estimate of 515 INR. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +38.78% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.